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Abstract
Herpes simplex virus-1 (HSV-1) causes lifelong infection affecting between 50 and 90% of the global population. In addition
to causing dermal lesions, HSV-1 is a leading cause of blindness resulting from recurrent corneal infection. Corneal disease is
characterized by loss of corneal immunologic privilege and extensive neovascularization driven by vascular endothelial
growth factor-A (VEGF-A). In the current study, we identify HSV-1 infected cells as the dominant source of VEGF-A during
acute infection, and VEGF-A transcription did not require TLR signaling or MAP kinase activation. Rather than being an
innate response to the pathogen, VEGF-A transcription was directly activated by the HSV-1 encoded immediate early
transcription factor, ICP4. ICP4 bound the proximal human VEGF-A promoter and was sufficient to promote transcription.
Transcriptional activation also required cis GC-box elements common to the VEGF-A promoter and HSV-1 early genes. Our
results suggest that the neovascularization characteristic of ocular HSV-1 disease is a direct result of HSV-1’s major
transcriptional regulator, ICP4, and similarities between the VEGF-A promoter and those of HSV-1 early genes.
Citation: Wuest T, Zheng M, Efstathiou S, Halford WP, Carr DJJ (2011) The Herpes Simplex Virus-1 Transactivator Infected Cell Protein-4 Drives VEGF-A Dependent
Neovascularization. PLoS Pathog 7(10): e1002278. doi:10.1371/journal.ppat.1002278
Editor: Roger D. Everett, University of Glasgow, United Kingdom
Received March 3, 2011; Accepted August 2, 2011; Published October 6, 2011
Copyright:  2011 Wuest et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIH R01 EY021238 to DC and a grant from the Wellcome Trust, WT086403MA to SE. TW was supported by NIAID training
grant, AI007633. Additional support includes an OUHSC PHF Presidential Professorship to DC, NIH/NCRR P20 RR017703, and an unrestricted grant from Research
to Prevent Blindness. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Dan-Carr@ouhsc.edu
Introduction
Herpes simplex virus-type 1 (HSV-1) is a neurotropic member
of the alpha herpesvirus family with worldwide seroprevalence
rates ranging from between 50–90%.[1,2]. Primary infection is
usually mild or asymptomatic in the immunocompetent host and
typically occurs in childhood or early adolescence following
inoculation of mucosal epithelial surfaces. During initial infection,
virions gain access to sensory nerve fibers and are transported to
neuronal cell bodies in the trigeminal ganglia where HSV-1
establishes a latent infection [3].
Although treatable, infection is life-long as a result of the
sequestration of latent virus from immunological surveillance [3].
Latency may be broken during times of stress or immunological
suppression resulting in the resumption of the lytic viral replication
cycle. Newly produced virions migrate down trigeminal nerve
fibers to epithelial surfaces where the reactivated virus resumes
lytic viral replication and infectious virions are released. Symptoms
of reactivation may be as mild as dermal vesicles or as severe as
herpes simplex encephalitis, the most common cause of sporadic
viral encephalitis in the world [4].
Despite the familiarity of dermal HSV-1 lesions, the most
significant clinical consequence of HSV-1 infection is secondary to
ocular HSV-1 infection. The trigeminal nerve provides sensation
to the lips, nose, and eye. Although the skin about the orofacial
region is the most frequent target of viral reactivation, all areas
innervated by the trigeminal nerve branches are susceptible and
recurrent bouts of corneal reactivation are not uncommon [3,5].
Repeated incidents of corneal infection lead to the breakdown of
corneal immunologic privilege and the development of an
immunoinflammatory disorder termed herpetic stromal keratitis
(HSK). Chronic inflammation elicits extensive corneal opacifica-
tion driven by host CD4+ T cells and neovascularization
secondary to disruption of the normal equilibrium between
corneal angiogenic and anti-angiogenic factors [5]. The immu-
noinflammatory nature of HSK is particularly vexing, as patients
refractory to treatment with antiviral medication may require
corneal transplantation [5]. Inflammation and corneal vascular-
ization promote corneal graft failure [5]. Thus, the HSK-
associated inflammatory processes which necessitate corneal
transplantation also substantially increase the risk of transplant
rejection in HSK patients [5].
Several different mechanisms contribute to corneal immuno-
logic privilege including the expression of immunosuppressive
factors, specialized tolerance-promoting DC populations, and the
avascular nature of the cornea [6–8]. Corneal avascularity may
play an important role during HSK, as corneal neovascularization
is highly predictive of future graft failure in HSV-1 affected
patients [5]. Furthermore, avascular tissues are universally
immunologically privileged [9–11]. The cytokine vascular endo-
thelial growth factor-A (VEGF-A) plays a particularly crucial role
in HSV-1-induced corneal neovascularization and drives both
angiogenesis and lymphangiogenesis [9,12–14]. A recent study in
our laboratory revealed that VEGF-A is expressed by HSV-1
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VEGF-A mRNA in HSV-1 infected cells [12]. However, the
mechanism by which VEGF-A expression is induced remains
unclear.
In the current study, we report the discovery that transcriptional
up-regulation of VEGF-A is dependent on HSV-1’s major
transcriptional regulator, infected cell protein 4 (ICP4). ICP4
binds the proximal human VEGF-A promoter and is sufficient for
transcriptional up-regulation of VEGF-A. Additionally, VEGF-A
expression requires a tract of GC-rich sequences with high
homology to the promoters of HSV-1 early (E) genes that ICP4
normally transactivates. Our results indicate that HSV-1 promotes
expression of VEGF-A via ICP4-dependent transactivation, and
this may be the result of sequence similarity between HSV-1 E
genes and the human proximal VEGF-A promoter.
Results
Expression of VEGF-A In Vitro and In Vivo by HSV-1
Infected Cells
The human cornea is normally devoid of blood and lymphatic
vessels due to low expression of (lymph)angiogenic cytokines and
abundant expression of anti-(lymph)angiogenic factors [6,8,10,11].
Our group has previously described the expression of the pro-
(lymph)angiogenic cytokine VEGF-A by HSV-1 infected corneal
epithelial cells which drives lymphangiogenesis following HSV-1
infection [12]. Increased expression of VEGF-A was at least
partially the result of transcriptional up-regulation as mice
expressing GFP under the proximal human VEGF-A promoter
showed selective induction of GFP within HSV-1 antigen-positive
cells at 36 hours post infection (PI) with HSV-1 strain McKrae
(Figure 1A). Likewise, GFP reporter expression was detectable by
12 hours PI (Figure 1B). Real time PCR analysis of VEGF-A
mRNA relative to the housekeeping genes b-actin, TBP, and PPIA
demonstrated transcriptional up-regulation following HSV-1
infection in Tert-immortalized human corneal epithelial cells
(THCE) (Figure 1C, p,0.01). Likewise, HSV-1 infection of the
human embryonic kidney fibroblast 293 cell line yielded a similar
transcriptional up-regulation of VEGF-A in human cells
(Figure 1D). VEGF-A was also detected in cytoplasmic extracts
of 293 cells with the highest detectable concentration being found
at 6 hours PI (Figure 1E). VEGF-A promoter activity was also
assayed using a reporter vector driving firefly luciferase under the
proximal human VEGF-A promoter. Infection of 293 cells with
three different wild-type HSV-1 strains (-McKrae, KOS, and
SC16), and the homologous HSV-2 virus, all significantly induced
expression of the VEGF-A promoter luciferase reporter gene
(Figure 1F). Reporter expression peaked at 12 hours PI, which was
6 hours after VEGF-A levels peaked in the cytoplasm, possibly due
to the differential secretion of VEGF-A versus the non-secreted
luciferase reporter which was retained in cells. Thus, HSV-1
infection drove transcriptional up-regulation of VEGF-A and
protein expression both in vitro and in vivo.
VEGF promoter-driven GFP expression was only detected in
HSV-1 antigen-positive cells within the cornea during acute
infection [12]. However, HSV-1 antigen-negative cells expressing
GFP reporter were observed in limbal tissues, proximal to the
cornea (data not shown). Neutrophils contain preformed stores of
VEGF-A and could release VEGF-A during HSV-1 infection
without detectably expressing reporter for VEGF-A transcription
[15]. To determine the relative contribution of HSV-1 infected
versus uninfected cells to VEGF-A production in vivo, we utilized
the Cre-lox system to selectively excise the VEGF-A gene from
HSV-1 infected cells. Either C57BL/6 controls or mice with a
floxed VEGF-A gene (Flxd-VEGFA) were infected with either wild
type HSV-1 strain SC16 or a Cre-expressing HSV-1 recombinant
virus, which was derived from strain SC16 and expressed Cre
under the control of the HSV-1 ICP0 promoter (Figure 2A and B).
In C57BL/6 control mice, corneal VEGF-A concentrations did
not significantly differ at day 3 PI between mice inoculated with
wild type HSV-1 versus the Cre-expressing HSV-1 recombinant
(Figure 2C, p.0.05). However, in Flxd-VEGFA mice, VEGF-A
concentrations at day 3 PI were 75% lower in animals infected
with the Cre-expressing ICP0 recombinant virus relative to Flxd-
VEGFA miceinfected with wild type HSV-1 (Figure 2D). Based on
the fact that selective Cre-mediated excision of the VEGF-A gene
reduced VEGF-A levels by 4-fold, it appeared that HSV-1 infected
cells were the predominant source of VEGF-A during acute HSV-
1 infection.
VEGF-A Expression Was Not Dependent on the Innate
Pattern Recognition Receptor Adaptor Proteins MyD88
or TRIF
VEGF-A is expressed during a wide range of inflammatory
processes including wound healing, psoriasis, and following the
ligation of some toll-like receptors (TLR) [16,17]. HSV-1 infection
stimulates the TLRs 2, 3, 4, and 9 [18]. All TLRs depend on the
MyD88 and/or TRIF adaptor proteins for signal transduction
[19]. Therefore, we tested whether VEGF-A was TLR-dependent
using mice deficient in MyD88 (MyD88
2/2) or TRIF (TRIF
2/2).
Corneas of MyD88
2/2 mice and TRIF
2/2 or their respective
C57BL/6 and B6129 controls strains, were scarified and
inoculated with PBS or 10
5 PFU of HSV-1. Corneas were
harvested at 24 hours PI and assayed for VEGF-A levels by
cytokine bead array. HSV-1 infection induced VEGF-A expres-
sion to high and statistically equivalent levels in the corneas of
C57BL/6, MyD88
2/2, B6129, and TRIF
2/2 mice (Figure 3A
and B). While VEGF-A levels were slightly higher in TRIF
2/2
mice relative to B6129 controls, this difference was not significant
(Figure 3B, p.0.05). In addition, VEGF-A dependent corneal
lymphangiogenesis was equivalent in MyD88
2/2 and TRIF
2/2
Author Summary
Herpes simplex virus-type 1 is the leading cause of
infectious corneal blindness in the industrialized world.
Most of the morbidity associated with the virus is due to
the host response to episodic reactivation of latent virus.
Corneal immunologic privilege is associated with a
number of factors including the absence of blood and
lymphatic vessels. Conversely, corneal hem (blood)- and
lymph-angiogenesis driven by inflammation correlate with
the loss of privilege. Neovascularization is a common
phenomenon in HSV-1 keratitis that correlates with poor
prognosis. We have previously discovered HSV-1 elicits
corneal lymphangiogenesis through a unique mechanism
involving vascular endothelial growth factor (VEGF)-A
independent of that described for other insults including
transplantation or bacterial infection. However, the viral-
encoded product(s) that elicit host production of VEGF-A
is(are) unknown. In this paper, we have identified infected
cell protein-4 (ICP4) as the primary virus-encoded product
that drives VEGF-A expression. As VEGF-A is involved in
driving neovascularization associated with tumor growth
and metastasis, proteins that influence transcriptional
regulation of VEGF-A may be useful in the development
of adjunct therapy for such disparate diseases as cancer
and HSV-1 keratitis.
HSV-1 ICP4 and Lymphangiogenesis
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shown).
MAP kinase activation up-regulates VEGF-A expression in
tumors and following TLR ligation [20–22]. Activation of MEK
following Helicobacter pylori infection induces VEGF-A expression
through the transcription factors Sp1 and Sp3 [23]. The HSV-1
immediate early (IE) gene product, ICP27 activates JNK and p38
pathways [24], and the HSV-2 homolog of the HSV-1-encoded
protein kinase, US3, directly activates the MEK pathway [25].
Therefore, we sought to clarify if any of these signal transuction
pathways might play a role in HSV-1 stimulated VEGF-A
expression. Using 293 cells, we tested if HSV-1 induction of
VEGF-A mRNA accumulation was dependent on MEK1/2, p38,
or JNK1/2 signal transduction pathways using their respective
Figure 1. HSV-1 infection drives transcriptional upregulation of VEGF-A. (A) Representative image of a cornea from pVEGFA-GFP reporter
mice at day 3 PI with HSV-1 strain McKrae stained for HSV-1 antigen (red), GFP transcriptional reporter for VEGF-A (green) and DAPI (blue) (B) GFP
transcriptional reporter expression (green) with HSV-1 antigen (red) at 12 hours PI with HSV-1 strain McKrae. (C) Real time PCR of THCE cells at
12 hours PI with 3 pfu per cell HSV-1 strain McKrae with VEGF-A fold induction determined via the geometric means of VEGF-A induction relative to
the housekeeping genes b-actin, TBP and PPIA (** p,0.01). (D) Real time PCR of VEGF-A transcription in 293 cells infected with 3 pfu per cell HSV-1
strain McKrae also determined via geometric mean relative to b-actin, TBP and PPIA (** p,0.01) and (E) Levels of VEGF-A by cytokine bead array in
cytoplasmic extracts of 293 cells at the indicated times PI with 3 pfu per cell HSV-1 strain McKrae, expressed as pg of VEGF-A per ug of cytoplasmic
protein extract. (F) Transcriptional activity of the proximal human VEGF-A promoter was measured using a luciferase vector with luciferase driven by
the VEGF-A promoter (spanning base pairs 22018 to +50 bp relative to the transcription start site). Transfected 293 cells were infected with 3 pfu per
cell of either wild-type HSV-1 strains; McKrae, KOS, or SC16 or with 3 pfu per cell HSV-2 and assayed for luciferase activity at the indicated time PI.
Luciferase activity was normalized to the activity of uninfected 293 cells transfected with a promoterless luciferase vector, pGL3 (** p,0.01). All
figures are representative figures from individual experiments with an n=3/group for A–D. Extracts from 3 culture wells per time point were pooled
for E. Bars denote mean VEGF-A pg per mg of cytoplasmic protein 6 SEM.
doi:10.1371/journal.ppat.1002278.g001
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ment of cells with 10 mM of each inhibitor ($100 times the IC50
values of each drug) had no discernable effect on the up-regulation
of VEGF-A mRNA levels 12 hours PI relative to vehicle- treated
cells (Figure 3C). Therefore, neither MyD88-, TRIF-, MAP
kinase-, MEK1/2-, p38-, or JNK1/2-signal transduction pathways
appeared to be required for HSV-1 infection to induce VEGF-A
accumulation in HSV-1 infected cells.
VEGF-A Promoter Analysis
To clarify which promoter elements were required for HSV-1 to
induce expression from the VEGF-A promoter, we utilized
luciferase reporter plasmids containing human VEGF-A promot-
ers that ranged in size from 2068 base pair (bp) promoter that
spanned 22018 to +50 bp (relative to the transcription start site)
to a minimal 102-bp VEGF-A promoter that spanned 252 to
+50 bp (Figure 4A). Transfected 293 cells were then assayed for
luciferase expression at 12 hours PI with HSV-1 strain McKrae
(Figure 4A). Expression depended on a short stretch of DNA from
285 to 252 bp relative to the transcription start site. The absence
of HIF-1a elements (2975 to 2968 bp) or STAT3 elements
(2848 to 2840 bp), which mediate VEGF-A transcriptional up-
regulation in response to hypoxia and IL-6 respectively [25] did
not prevent HSV-1 from inducing a 10-fold increase in luciferase
expression from the 2790 to +50 BP promoter (Figure 4A).
EMSA analysis also demonstrated a distinct alteration in the
binding of nuclear proteins to biotinylated probe spanning 288
to +55 bp following infection with HSV-1. In uninfected 293
cells, nuclear protein extracts bound probe in discrete shifts,
possibly corresponding to either multimeric structures or distinct
Figure 2. HSV-1 infected cells are the dominant source of VEGF-A during acute HSV-1 infection. To assess the relative contribution of
HSV-1 infected or uninfected cells to global VEGF-A expression, C57BL/6 (A) or Flxd-VEGFA (B) mice were infected with either wild-type HSV-1 SC16 or
a derivative expressing Cre under the ICP0 promoter sequence resulting in the selective Cre-mediated ablation of VEGF-A expression in ICP0-Cre
infected Flxd-VEGFA cells. (C) VEGF-A levels in the corneas of wild-type C57BL/6 control animals which were scarified only (UI) or scarified and
infected with 10
5 pfu of HSV-1 strain SC16 or SC16 expressing Cre under the ICP0 promoter (ICP0-Cre) and harvested at 24 hours PI, (** p,0.01, NSD
non-significant difference). (D) VEGF-A levels were not elevated in the corneas of animals in which the VEGF-A allele was floxed after receiving ICP0-
Cre relative to UI controls. However, VEGF-A was up-regulated in animals received HSV-1 strain SC16 at 24 hours PI. (** p,0.01). Figures A and B are
summaries of 2 experiments with 2 corneas per sample, total n=4 samples in UI group and a total n=5 samples in each infected group. Bars denote
mean VEGF-A pg/mg of cornea wet mass 6 SEM.
doi:10.1371/journal.ppat.1002278.g002
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harvested 6 hours after HSV-1 McKrae infection contained
proteins that primarily bund the VEGF-A promoter probe in a in
a broad band of lower mobility. The same probe was not bound
to detectable levels by nuclear extracts harvested from HSV-1
strain McKrae-infected cells at 12 hours PI (Figure 4B). Howev-
er, during infection with the less virulent strain HSV-1 strain
KOS, an EMSA shift was still detectable at 12 hours PI (data not
shown).
The original construction of the luciferase reporter plasmid
driven by the 285 to 50 bp segment of the human VEGF-A
promoter resulted in the loss of the pGL3 multiple cloning site
(MCS). A new and equivalent luciferase expression vector was
constructed that retained a MCS, and thus allowed site-directed
mutagenesis of the proximal VEGF-A promoter from 288 to
+55 bp relative to the transcription start site. The resulting
plasmid was denoted [pVA8855] and performed equivalently to
the original plasmid vector. Three consensus ‘‘GC box’’ sequences
are present between 85 to 252 bp of the VEGF-A promoter, and
which may serve as binding sites for transcription factors of the Sp
family [22] (Figure 4C).
We tested the relevance of these GC box sequences in the
VEGF-A promoter by mutating individual GGGCGG consensus
sequences, or combinations thereof, to the mutant sequence
AACACA (Figure 4C). Human 293 cells were transiently
transfected with the wild type VEGF-A promoter construct,
pVA8855, or 1 of 8 GC-box mutant plasmids. After 48 hours,
cells were mock-inoculated or inoculated with 3 pfu per cell of
HSV-1 strain McKrae, and luciferase levels were compared at
12 hours PI (Figure 4D). Mutation of GC-box 1 alone (285 to
280 bp) or GC-box 2 alone (274 to 269 bp) did not preclude
HSV-1 induction of the luciferase reporter gene (Figure 4D). In
contrast, deletion of GC-box 3 (258 to 253 bp) or any
permutation of two or more GC-boxes ablated the capacity of
HSV-1 to induce luciferase expression from the minimal VEGF-
A promoter represented by 288 to +50 bp relative to the
transcriptional start site (Figure 4D).
Although GC box sequences were required for VEGF-A
promoter transcriptional up-regulation, we did not detect binding
of nuclear proteins to GC boxes using proximal VEGF-A
promoter probes. EMSA assays of native or GC box mutated
probes (Figure S1A) spanning 288 to 250 bp relative to the
transcription start site did not show differential EMSA shifts
between probes using either uninfected or 6 hour PI nuclear
extracts (Figure S1B). However, we presume this negative result
was due to extensive secondary structure within this region of the
human VEGF-A promoter blocking transcription factor binding as
probe containing an isolated GC box probe was shifted using
nuclear extracts from 0, 6, and 12 hours PI (Figure S1C).
No Apparent Role for EGR-1
HSV-1 infection up-regulates the transcription factor EGR-1
which promotes transcription at sites within the HSV-1 genome
bearing the core consensus sequence GCGGGGGCG [26]. The
region of the human VEGF-A promoter spanning 285 to 252 bp
contains two EGR-1 binding sequences, and EGR-1 drives
expression of VEGF-A following growth factor stimulation [22].
Western blot analysis of HSV-1 infected 293 cells for EGR-1 did
not demonstrate up-regulated expression of EGR-1 until 12 hours
PI (Figure 5A and B). In contrast, VEGF-A transcript was
significantly augmented (p,.01) as early as 3 hours PI suggesting
that an EGR-1 independent pathway activated the VEGF-A
promoter in HSV-1 infected cells (Figure 5C).
To test for the possibility of either an indirect or direct role for
EGR-1, we used siRNA to reduce EGR-1. Transfection with
siRNAs against EGR-1 (4538 and 4539) blocked EGR-1 up-
regulation following HSV-1 infection with EGR-1 expression
reduced by roughly 89% (comparison between HSV-1 infected
non-transfected cells versus HSV-1 infected cells treated with
siRNA 4539, p,0.01, Figure 5D). However, even in the absence
of EGR-1 up-regulation VEGF-A transcript expression was up-
Figure 3. VEGF-A expression is not dependent on the TLR
adaptors MyD88 or TRIF. VEGF-A levels expressed as pg of VEGF-A
per mg of cornea wet mass at 24 hours after scarification alone (UI) or
infection with 10
5 pfu of HSV-1 strain McKrae in either (A) C57BL/6
controls or MyD882/2 animals or (B) B6129 controls or TRIF2/2
animals. (C) Human 293 cells were plated and fold induction of VEGF-A
transcript after infection with 3 pfu per cell HSV-1 strain McKrae.
Treatment with inhibitors of MEK1/2 (U0126), JNK1/2 (SP600125) or p38
(SB206580) at 10 mM concentrations also did not block VEGF-A
transcription relative to uninfected, vehicle-treated control. Bars denote
6 SEM. A and B are summaries of two experiments with total n=6/
group. Panel C is a representative figure of 2 experiments, n=3/group/
experiment. Fold induction values were normalized to VEGF-A levels in
uninfected, vehicle-treated controls using the geometric mean of fold
induction values relative to the housekeeping genes b–actin, TBP, and
PPIA. (** p,0.01, *,0.05, NSD non-significant difference).
doi:10.1371/journal.ppat.1002278.g003
HSV-1 ICP4 and Lymphangiogenesis
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and tended to increase following siRNA 4538 treatment as well
(Figure 5E).
EGR-1 is constitutively expressed in 293 cells, and EGR-1
affects HSV-1 gene expression [26]. Thus, EGR-1 knockdown
may indirectly affect pathways that could influence VEGF-A
transcription. We tested for a direct role for EGR-1 via site specific
mutagenesis of EGR-1 binding sequences within the VEGF-A
promoter. EGR-1 is a C2H2-type three zinc finger transcription
factor with the fingers binding the triplets GCG, G/T GG, and
GCG respectively [27]. EGR-1 and GC box elements within the
285 to 252 bp region of the VEGF-A promoter overlap so only
modification to the first triplet of EGR-1 sites could be made
without also altering GC box sequences (Figure 5F). In fact,
mutation of the first triplet is sufficient to abrogate EGR-1 binding
[28,29]. Mutation of EGR-1 consensus sequences had no effect on
VEGF-A promoter driven luciferase expression following HSV-1
infection (pVA8855 versus DEGR-1 or promoterless reporter
vector pGL3, Figure 5G). Although EGR-1 could conceivably
contribute to transcription of the VEGF-A gene at late stages of
HSV-1 infection, we did not observe a requirement for either
EGR-1 up-regulation or the presence of EGR-1 consensus sites for
transcriptional up-regulation of VEGF-A.
HSV-1 ICP4 Is Required for VEGF-A Transcription and
Reporter Expression
Two experiments were conducted with biochemical inhibitors to
determine if HSV-1’s capacityto induce the VEGF-Apromoterwas
dependent upon the de novo synthesis of viral or cellular proteins in
HSV-1 infected cells. The first experiment used the protein
synthesis inhibitor cycloheximide. When protein translation was
allowed to occur, 3 pfu per cell of HSV-1 McKrae induced a 10-
fold increase in VEGF-A mRNA levels in THCE cells at 12 hours
PI (Figure 6A). A second experiment was conducted with the
guanosine analogue acyclovir to determine if restriction of HSV-1
DNA synthesis and ,445 HSV-1 late (L) proteins affected HSV-1’s
capacity to induced VEGF-A synthesis [30,31]. Infection with
HSV-1 McKrae induced VEGF-A mRNA to high and equivalent
levels in THCE cells treated with vehicle or 200 mM acyclovir
(Figure 6B). These data excluded the possibility that HSV-1 virion
attachment and/or entry were sufficient to induce VEGF-A mRNA
accumulation. Rather, the data suggested that de novo protein
synthesis during the initial hours of HSV-1 infection was necessary
to induce VEGF-A gene expression in HSV-1 infected cells.
To explore the possibility that one or more HSV-1 proteins
might contribute to VEGF-A transcriptional up-regulation, the
capacity of wild type HSV-1 strain KOS to induce VEGF-A
Figure 4. VEGF-A promoter analysis. (A) Human 293 cells were transfected with luciferase reporter plasmids (pGL3) driven by the indicated
segments of the human VEGF-A promoter relative to the transcription start site. Luciferase activity was measured at 12 hours PI with 3 pfu per cell
HSV-1 strain McKrae. HSV-1 induced upregulation of luciferase activity required a GC-rich segment spanning base pairs 285 to 252 diagramed in (C).
(B) EMSA showing differential binding of nuclear proteins to VEGF-A 288 to +55 base pair probe. Free probe denoted by the solid black arrow was
shifted following addition of nuclear extracts from uninfected 293 cells and probe mobility was further retarded by nuclear proteins harvested from
cells at 6 hours PI with 3 pfu per cell HSV-1 (hollow arrow). By 12 hours PI, probe mobility was no longer shifted by nuclear extracts. (C) Diagram of
the proximal human VEGF-A promoter showing ‘‘GC box’’ consensus site for transcription factors of the Sp1 family. Bases shown in red indicate base
changes to render a luciferase construct driven by base pairs 288 to +55 of the human VEGF-A promoter to being devoid of individual or multiple GC
box sequences. (D) Luciferase activity was measured in 293 cells transfected with either wild-type pVA8855 reporter plasmid or the indicated GC box
mutations at 12 hours PI with 3 pfu per cell HSV-1 strain McKrae. Representative figure from 2 experiments, n=3/group/experiment.
doi:10.1371/journal.ppat.1002278.g004
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HSV-1 KOS-derived mutants, HSV-1 n12 [32] and HSV-1 hr94
[33]. HSV-1 n12 is an ICP4
2 null virus that fails to encode HSV-
1’s major transcriptional regulator, infected cell protein 4 (ICP4),
and consequently fails to exit the IE phase of protein accumulation
[32]. As a result, HSV-1 ICP4
2 null viruses over express four IE
proteins (ICP0, ICP22, ICP27, and ICP47) and fail to efficiently
synthesize the other ,70 E and L proteins encoded by the HSV-1
genome. The second HSV-1 mutant, hr94, fails to encode HSV-1
origin-binding protein (OBP), which is necessary for the onset of
viral DNA synthesis [33]. As a result, HSV-1 OBP
2 null viruses
efficiently synthesize ,30 IE and E proteins, but exhibit more
restricted expression of ,45 HSV-1 L proteins.
The efficiency of VEGF-A mRNA induction was compared in
293 cells inoculated with 3 pfu per cell of wild type HSV-1 KOS
versus the KOS-derived ICP4
2 null (n12) or OBP
2 null (hr94)
viruses. HSV-1 KOS induced an average 8-fold increase in
VEGF-A mRNA levels at 12 hours PI (Figure 6C). Likewise, the
HSV-1 OBP
2 null virus induced an average 6-fold increase in
VEGF-A mRNA levels (Figure 6C). In contrast, infection with an
HSV-1 ICP4
2 null virus did not detectably induce VEGF-A
mRNA accumulation (Figure 6C).
Figure 5. EGR-1 is not required for VEGF-A Upregulation. (A) Human 293 cells were infected with 3 pfu per cell HSV-1 McKrae, and nuclear
protein extracts harvested at the indicated time PI were assayed for EGR-1 by western blot. (B) Densitometry values of EGR-1 western blots at the
indicated time PI. (C) Fold induction of VEGF-A mRNA relative to the b-actin, TBP and PPIA at the indicated time PI with 293 cells infected with 3 pfu
per cell HSV-1 McKrae. (D) EGR-1 mRNA fold induction relative to b-actin, TBP and PPIA following HSV-1 infection in 293 cells treated with either
vehicle, negative control siRNA, or two independent siRNAs against EGR-1 (4538 and 4539). Individual fold induction values were determined via
geometric means of fold induction of VEGF-A transcript relative to the housekeeping genes b-actin, TBP and PPIA. Reduction relative to respective
uninfected controls was approximately 60%. The EGR-1 transcript was not up-regulated following HSV-1 infection in siRNA treated groups.
Comparison between HSV-1 infected non-transfected cells versus HSV-1 infected cells treated with siRNA 4539 for EGR-1 transcript showed a
reduction of approximately 89% and greater than 95% reduction for cells treated with siRNA 4538 relative to non-transfected, HSV-1 infected cells,
p,0.01. (**p,0.01, * p,0.05). (E) VEGF-A fold induction following siRNA treatment. Transcriptional up-regulation occurred in the absence EGR-1 up-
regulation in 4539 treated cells and tended toward up-regulation in 4538 treated cells as well. (F) Diagram of the human VEGF-A promoter from base
pairs 288 to 250 showing GC box and EGR-1 consensus sequences along with mutations introduced to obviate EGR-1 binding to reporter plasmid
shown in red (DEGR-1). (G) Luciferase activity of 293 cells transfected with either control VEGF-A 288 to +55 (pVA8855) base pair promoter driven
reporter construct, DEGR-1 reporter, or the promoterless control reporter backbone pGL3, after infection with 3 pfu per cell HSV-1 strain McKrae.
(** p,0.01). (** p,0.01, * p,0.05). Figures are representative of 2 experiments, C–E and F used an n=3/group/experiment. Bars denote arithmetic
mean of individual fold induction values 6 SEM.
doi:10.1371/journal.ppat.1002278.g005
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PLoS Pathogens | www.plospathogens.org 7 October 2011 | Volume 7 | Issue 10 | e1002278Figure 6. The HSV-1 transactivator ICP4 is required for VEGF-A expression. Human 293 cells were plated and infected with 3 pfu per cell
HSV-1 strain McKrae. Fold induction of VEGF-A transcript expression was determined via geometric means of fold induction of VEGF-A transcript
relative to the housekeeping genes b-actin, TBP and PPIA. (A) Inhibition of protein synthesis with cycloheximide (100 mg/mL) blocked upregulation of
VEGF-A following HSV-1 infection while (B) inhibition of viral DNA synthesis with acyclovir (200 mM) had no significant effect. (C) ICP4 dependence
was tested using human 293 cells infected with 3 pfu per cell of wild type HSV-1 KOS or KOS-derived mutants lacking ICP4 (ICP4
2 null virus) or the
HSV-1 origin binding protein (OBP
2 null virus). VEGF-A transcript was measured via real time RT-PCR relative to b-actin, TBP and PPIA. (*p,0.05
relative to uninfected control cells). (D) Human 293 cells transfected with pVA8855 or the promoterless luciferase control plasmid, pGL3. Luciferase
activity was measured at 12 hours PI with HSV-1 KOS, ICP4
2 null, or OBP
2 null virus. (E) VEGF-A mRNA levels in human 293 cells infected with 3 pfu
per cell HSV-1KOS or an HSV-1 ICP0
2 null virus that fails to make the IE co-transactivator protein, ICP0; both viruses significantly up-regulated VEGF-A
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PLoS Pathogens | www.plospathogens.org 8 October 2011 | Volume 7 | Issue 10 | e1002278An experiment was conducted to determine if ICP4 played a
role in the capacity of HSV-1 to induce the minimal VEGF-A
promoter represented by 288 to +55 bp in luciferase reporter
plasmid construct pVA8855 (Figure 4D). Specifically, 293 cells
were transfected with pVA8855 or a promoterless control plasmid,
pGL3, for 48 hours, and then the cells were infected with 3 pfu
per cell of wild type, ICP4
2 null, or OBP
2 null HSV-1. Luciferase
reporter gene expression was significantly elevated in 293 cells
inoculated with HSV-1 KOS or the HSV-1 OBP
2 null virus
(Figure 6D, **p,.01). In contrast, inoculation with the HSV-1
ICP4
2 null virus failed to induce luciferase expression from the
VEGF-A promoter in pVA8855 (Figure 6D). Tests were
conducted to determine if the IE transactivator ICP0 was
necessary for HSV-1 to induce VEGF-A mRNA accumulation.
Human 293 cells infected with an HSV-1 ICP0
2 null virus, 7134,
transcribed VEGF-A mRNA at levels equivalent to cells infected
with the parental virus HSV-1 KOS (Figure 6E). Likewise, HSV-1
KOS and HSV-1 ICP0
2 null virus were compared for their ability
to induce VEGF-A production in vivo in the corneas of interferon-
signaling deficient CD118
2/2 mice, in which HSV-1 ICP0
2 null
viruses may replicate to nearly wild type levels during the first
24 hours PI [34]. In these in vivo tests, VEGF-A levels were
significantly up-regulated at 24 hours PI in the corneas of mice
inoculated with wild type HSV-1 KOS or the ICP0
2 null virus
relative to mock-infected controls (Figure 6F, **p,.01). Thus,
ICP0 is not essential for HSV-1 infection to induce VEGF-A
mRNA or protein accumulation.
We verified these conclusions in an in vivo test using pVEGFA-
GFP reporter mice. Following inoculation of mouse corneas with
HSV-1 ICP4
2 null virus, HSV-1 antigen positive cells were
detectable in the cornea at 12 hours PI, but these sites did not co-
localize with induction of the pVEGFA-GFP reporter in these
transgenic mice (Figure 6G). In contrast, mouse corneas inoculated
with wild type KOS (Figure 6G) or HSV-1 OBP
2 null virus (data
not shown) exhibited a clear co-localization of HSV-1 antigen-
positive cells and induction of the pVEGFA-GFP reporter gene.
Although low level GFP expression was observed in HSV-1
antigen-positive cells in reporter mice infected with ICP4
2 null
virus, expression was extremely faint compared to that observed in
KOS infected cells and was comparable to the transient GFP
expression observed following corneal scarification procedure
required for HSV-1 infection.
As an additional control we tested the ability of an HSV-1
ICP27
2 null virus, d27-1 [35], to induce the minimal VEGF-A
promoter in plasmid pV8855. ICP27, like ICP4, is a viral IE
protein that is required for the efficient expression of E and L
proteins [36]. Hence, HSV-1 ICP27
2 null viruses over express
viral IE proteins including ICP4 (Figure S3A and B), but fail to
express most of other ,70 E and L HSV-1 proteins [35].
Consistent with the observed over expression of ICP4, cells
inoculated with an HSV-1 ICP27
2 virus induced the VEGF-A
promoter in pV8855 to express 7-fold and 60-fold higher levels of
luciferase than was observed in cells infected with wild type HSV-1
or an HSV-1 ICP4
2 virus, respectively (Figure S3C). This
correlation between ICP4 over expression and elevated luciferase
reporter induction in ICP27
2 virus-infected cells suggested that
the major transcriptional regulator of HSV-1, ICP4, might play a
direct role in transcriptional induction of the VEGF-A promoter
rather than acting via an indirect mechanism that required the
synthesis of HSV-1 E or L proteins.
HSV-1 ICP4 Binds the Proximal VEGF-A Promoter
To test for a role for ICP4 in the complex binding the proximal
VEGF-A promoter, nuclear extracts were harvested from 293 cells
following infectionwithHSV-1 KOS, or ICP4
2 null virus or OBP
2
null virus. Infection with HSV-1 KOS or the OBP
2 null virus led to
a change in the EMSA shift of VEGF-A 288 to +55 probe within
6 hours PI that remained through 12 hours PI but no change in the
probe shifts was observed in ICP4
2 virus-infected nuclear extracts
relative to uninfected extracts (Figure 7A). The ICP4 binding
consensus DNA sequence A/GTCGTCNNNNYCGRC (N=any
nucleotide, Y=pyrimidine, R=purine) is not present in the human
VEGF-A promoter region [37,38]. However, ICP4 undergoes
extensive post-translational modifications that alter sequence
affinity and ICP4 binds a wide variety of sequences with no
apparent relation to its consensus sequence [37–40]. To determine
if ICP4 bound the humanVEGF-Apromoter,288 to +55 base pair
probe was incubated with nuclear protein extracts harvested from
cells at 6 hours PI and assayed for mobility supershift following
addition of monoclonal antibody against HSV-1 ICP4. Addition of
anti-ICP4 retarded probe/nuclear protein mobility establishing
binding of ICP4 to the VEGF-A proximal promoter region
(Figure 7B). ICP4 interaction with the proximal human VEGF-A
promoter did not require GC box sequences from 285 to 252 bp
relative to the transcription start site (Figure S2A). Furthermore,
EMSA supershift analysis of probe spanning either 288 to 250 bp
or probe spanning 250 to +55 bp indicated that the ICP4 binding
site or sites were localized to 250 to +55 base pairs relative to the
transcription start site (Figure S2B and C). ICP4 binding to the
proximal human VEGF-A promoter was specific. Binding was not
observed using oligo probe spanning an irrelevant sequence of the
VEGF-A(bp 21513 to21338 relative to the transcriptionstart site,
Figure 7C). In addition, nuclear protein complexes from HSV-1
infected cell extractswere alsocompetitivelydisassociated from288
to +55 bp probe by molar excesses of unlabeled oligo containingthe
ICP4 consensus sequence (Figure 7D).
We next sought to determine if ICP4 expression was sufficient to
drive transcriptional enhancement of VEGF-A. As with 293 and
THCE cells, luciferase reporter activity for the human proximal
VEGF-A promoter is up-regulated in human primary dermal
keratinocytes (HPKs) in an ICP4-dependent fashion (Figure 8A).
To determine if ICP4 was sufficient for reporter expression, HPKs
were transfected with either promoterless luciferase vector pGL3
or pVA8855 and transduced with adenoviral vector expressing the
reverse tetracycline-controlled transactivator protein (AdrtTA) and
either a negative control adenvoviral vector AdNull or vector
expressing ICP4 under the control of a tetracycline response
element (AdICP4). After incubation for 30 hours in the presence
or absence of 3 mm doxycycline, cells were assayed for luciferase
activity. The reporter was significantly up-regulated in AdICP4
mRNA levels. (F) Mice lacking type I interferon responses due to deficiency in the type I interferon receptor (CD118
2/2) were infected with HSV-1 KOS
or HSV-1 ICP0
2 null virus. Corneas were harvested at 24 hours PI with 10
5 pfu of HSV-1 and analyzed for VEGF-A levels by cytokine bead array,
expressed as pg of VEGF-A per mg of cornea wet mass. VEGF-A was induced by inoculation with HSV-1 KOS or HSV-1 ICP0
2 null virus (** p,0.01
relative to uninfected, scarified controls). (G) Reporter mice expressing GFP under the human VEGF-A promoter were analyzed for HSV-1 antigen (red)
and GFP (green) along with DAPI (blue) at 12 hours PI with either HSV-1 KOS or HSV-1 ICP4- virus. A and B are representative figures of two
experiments, n=3/group/experiment. Fold induction values were normalized to VEGF-A levels in uninfected, vehicle-treated controls. Panels C and D
are representative of two experiments, n=3/group/experiment. Panel E is a summary of two experiments, n=6/group. Panel F is representative of
two experiments with an n=3/group/experiment. Bars denote mean 6 SEM. (** p,0.01, *,0.05, NSD=non-significant difference).
doi:10.1371/journal.ppat.1002278.g006
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vehicle-treated and AdNull-treated controls (Figure 8B). We also
tested ICP4 sufficiency for VEGF-A promoter activation in vivo
by cornea stromal co-injection of either AdrtTA and AdNull or
AdrtTA and AdICP4 into pVEGFA-GFP reporter mice. Mice
were kept on doxycycline treated water (2 mg/mL) for 5 days
before eyes were harvested and examined for GFP expression by
confocal microscopy. The VEGFA-GFP reporter was not
detectably induced in mouse corneas transduced with AdNull,
but was abundantly expressed in AdICP4-transduced corneas
(Figures 8C and D, respectively). Thus, ICP4 was required for
transcriptional up-regulation of VEGF-A during HSV-1 infection
and sufficient to augment transcription at the proximal human
VEGF-A promoter.
Blockade of VEGF-A and its receptor VEGFR-2 are sufficient
to block HSV-1- induced lymphangiogenesis but not angiogenesis
[5,12,41,42]. Lymphatic vessels typically express the VEGF family
receptors VEGFR-2 and VEGFR-3 [9] while blood vessels express
VEGFR-1 and VEGFR-2 [9], both of which bind VEGF-A [13].
We hypothesized that the mere partial dependence on blood vessel
Figure 7. ICP4 binds the human VEGF-A promoter. (A) Image of EMSA using probe spanning base pairs 288 to +55 relative to the VEGF-A
transcription start site with nuclear protein extracts (NPE) from 293 cells infected with HSV-1 KOS, HSV-1 KOS ICP4-, or the replication deficient control
HSV-1 OBP-. Nuclear extracts were harvested at the indicated time PI with 3 pfu per cell of HSV-1. Infection with either HSV-1 KOS or HSV-1 OBP- led
to changing EMSA shifts of VEGF-A probe, no shift was observed in cells infected with ICP4 deficient virus relative to uninfected control extracts. Free
probe (P) indicated with a solid arrow denotes the probe and nuclear protein complex at 6 hours PI whereas the hollow arrow denotes the antibody
shifted probe/nuclear protein complex at 12 hours PI. Representative of two experiments. (B) Supershift analysis was performed to determine if ICP4
bound 288/+55 probe from nuclear protein extracts of 293 cells infected with 3 pfu per cell HSV-1 KOS with or without antibody against ICP4 at
6 hour PI. The antibody further retarded the probe/nuclear protein complex; free probe (P) indicated by a solid arrow denotes the probe and nuclear
protein complex whereas the hollow arrow denotes the antibody shifted probe/nuclear protein complex. (C) As a negative control for binding
specificity, nuclear extracts were incubated with an oligo probe spanning an irrelevant region of the VEGF-A promoter (base pairs 21513 to 21338
relative to the transcription start site). Nuclear protein binding was not observed in EMSAs using UI or HSV-1 infected nuclear protein extracts
incubated with either isotypic control or antibody against ICP4. (D) EMSA of 288/+55 VEGF-A probe incubated with HSV-1 infected nuclear protein
extracts and increasing molar excesses of unlabeled oligonucleotide containing the ICP4 consensus site.
doi:10.1371/journal.ppat.1002278.g007
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PLoS Pathogens | www.plospathogens.org 10 October 2011 | Volume 7 | Issue 10 | e1002278Figure 8. ICP4 expression is required and sufficient to drive VEGF-A transcription. (A) To determine if expression of ICP4 was required for
activation of transcription at the VEGF-A promoter, human primary dermal keratinocytes were transfected with pGL3 or pVA8855 luciferase reporter
were infected with 3 pfu per cell HSV-1 KOS, HSV-1 ICP4
2 null virus, or HSV-1 OBP
2 null virus and assayed for luciferase activity at 8 hours PI. (B) We
tested to see if ICP4 expression was sufficent to drive transcription from the VEGF-A promoter by transfecting human primary dermal keratinocytes
transfected with pVA8855 luciferase reporter. Transfected cells were then transduced with 10 pfu per cell of adenoviral vectors expressing the reverse
tetracycline-regulated transactivator as well as either negative control vector (AdNull) or vector expressing TRE-driven ICP4 (AdICP4) and treated with
either vehicle or vehicle plus 3 mM doxycycline. Luciferase activity was measured at 30 hours post-transduction. (C) The corneas of pVEGFA-GFP
reporter mice were injected with a combination of either 10
5 pfu AdNull and 10
4 pfu AdrtTA or (D) 10
5 pfu AdICP4 and 10
4 pfu AdrtTA and treated
with doxycycline via drinking water (2 mg/mL) for 5 days prior to examination via confocal microscopy for GFP reporter for VEGF-A (green, nuclei
stained with DAPI shown in blue). (E) Transcript abundance of the VEGF family members; VEGF-A, VEGF-B, and PGF was measured by real-time RT-PCR
in human primary keratinocytes at 8 hours PI with either HSV-1 KOS, ICP4-, or OBP- virus. VEGF-C and VEGF-D were not detected in any group.
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VEGFR-1 ligands during HSV-1 infection. Transcript abundance
for all five human VEGFs; VEGF-A, VEGF-B, VEGF-C, VEGF-
D, and PGF was assayed by real-time RT-PCR in human primary
keratinocytes infected with HSV-1 KOS, ICP4
2 null, or OBP
2
null virus. Transcripts encoding the VEGFR-3 ligands VEGF-C
and VEGF-D were not detected by RT-PCR (Figure 8E).
Likewise, the VEGFR-1 ligand VEGF-B was not up-regulated
HSV-1 infection (Figure 8E). However, transcript for the VEGFR-
1 ligands VEGF-A and PGF significantly increased following
inoculation of human primary keratinocytes with HSV-1 KOS or
OBP
2 null virus (Figure 8E). As with VEGF-1 mRNA levels,
increased transcript abundance of PGF mRNA was also ICP4-
dependent (Figure 8E). At the time of writing it is unclear whether
ICP4-dependent transcription of PGF occurs in the same direct
fashion as with VEGF-A or whether ICP4 and HSV-1 indirectly
activate transcription at the PGF promoter. However, our results
indicate that HSV-1 infection induces mRNA transcription from
cellular genes that encode two VEGFR1 ligands, and this
induction is ICP4-dependent. Further testing will be required to
determine if chemical or antibody-mediated blockade of VEGF-A
and PGF ligands is sufficient to stop the angiogenic sequelae
characteristic of ocular HSV-1 infection.
Discussion
Despite the longstanding awareness of the impact of angiogen-
esis and contribution of VEGF-A during ocular HSV-1 infection
[5,41,42], recognition of HSV-1 infected cells as a source of
VEGF-A has occurred only recently [12]. Our study suggests that
the preeminent source for VEGF-A during acute ocular infection
is HSV-1 infected cells on the basis co-localization of VEGFA-
GFP reporter with HSV-1 antigen (Figure 1, [12]) and
experiments using HSV-1 infected cell-specific deletion of
VEGF-A (Figure 2A). We had initially hypothesized that VEGF-
A expression was driven by TLR or other pattern recognition
receptors. TLR ligation drives expression of VEGF-A as well as
other VEGF family members [16,43,44]. All TLRs signal through
either MyD88 and/or TRIF [19]. Yet, MyD88 and TRIF
deficiency had no impact on VEGF-A expression following
HSV-1 inoculation. This result could be reconciled with functional
redundancy between MyD88 and TRIF signaling TLRs allowing
expression in the sole absence of either MyD88 or TRIF, but not
in animals deficient in both genes. However, that appears unlikely
as corneal infection with vesicular stomatitis virus does not drive
detectable pVEGFA-GFP reporter expression in reporter mice
[12] despite activation of MyD88- and TRIF-dependent TLRs
[45,46] as well as other pattern recognition receptors such as
LRRFIP1 and RIG-I [14,47,48]. The possibility of TLR-driven
VEGF-A expression during HSV-1 infection would also be
particularly unlikely in human cells as the preeminent TLR
mediating HSV-1 recognition in humans is TLR3 [49]. TLR3/
TRIF signaling profoundly suppresses VEGF-A through interfer-
on pathways [50] and is thus, unlikely to make a positive
contribution during HSV-1 infection.
Conceivably non-TLR pattern recognition receptors could
contribute to VEGF-A expression. However, ICP4- HSV-1 would
be expected to activate similar pattern recognition receptors as
parental HSV-1 yet did not up-regulate VEGF-A transcript. A null
adenoviral vector also did not stimulate reporter for VEGF-A,
while AdICP4 drove reporter expression in vitro and in vivo.
Thus, two different model systems with considerable overlap for
stimulation of pattern recognition receptors did not drive VEGF-A
expression without concurrent expression of ICP4. In fact, innate
pattern recognition may decrease VEGF-A expression. Viral
pattern recognition receptors almost universally activate interferon
pathways [51,52], and interferon inhibits expression of VEGF-A
[50].
Transcriptional up-regulation of VEGF-A was dependent on
the HSV-1 transactivator ICP4. This observation and sequence
similarities between the VEGF-A promoter and HSV-1 E gene
promoters suggests that rather than being an innate response to
viral infection, the HSV-1 transcriptional regulation program
drives VEGF-A expression. VEGF-A mediates a number of
responses that may be beneficial to the pathogen such as
suppression of DC maturation [53] as well as growth and
chemotaxis of neuronal axons [54], the ultimate target of HSV-
1. All wild-type HSV-1 strains tested to date have maintained the
ability to up-regulate VEGF-A transcript and promoter reporter.
The highly homologous virus HSV-2, whose ICP4 is functionally
interchangeable with HSV-1 ICP4 [55], also drove expression of
VEGF-A. Shared expression of VEGF-A by these disparate viruses
is suggestive of a natural selection mechanism. But activation of
transcription of VEGF-A was maintained despite repeated passage
within Vero cells, a fibroblast line expected to be deficient in the
receptors for VEGF-A; VEGFR-1/2, though not specifically
tested. In the absence of VEGFR-1/2 no conceivable survival
benefits of VEGF-A expression would exist in culture, and a
specifically evolved pathway would presumably be lost. Thus,
rather than being an evolved pathway HSV-1 induced VEGF-A
expression could be an incidental consequence of similarity
between VEGF-A and HSV-1/2 promoters.
ICP4 bound the VEGF-A promoter independently of the three
GC box sequences required for transcriptional up-regulation. In
addition, we were not able to detect nuclear protein binding to
these motifs in the VEGF-A promoter probe. We detected binding
of nuclear proteins to probe containing a single isolated GC box
(Figure S1). Therefore, we presume the lack of nuclear protein
binding to GC boxes within VEGF-A promoter probe was due to
the extensive secondary structure present within the VEGF-A
promoter probe from 285 to 252 bp. The most obvious GC box
binding candidate is the endogenous transcription factor Sp1
which is heavily phosphorylated during HSV-1 infection and plays
a role in IE and E gene transcription [38,56,57]. However, it
should be noted other members of the Sp transcription factor
family also bind GC box sequences.
ICP4 bound within a region spanning bp 250 to +55 relative to
the VEGF-A transcription start site (Figure S2). There are no
sequences within this region with perfect homology to the ICP4
consensus binding sequence ATCGTCNNNNYCGRC (N=any
nucleotide, Y=pyrimidine, R=purine, 12). This point is not a
cause for concern as ICP4 affinity is degenerative with strong
interactions involving sequences with no resemblance to the core
consensus sequence [37–40,58]. ICP4 and DNA interactions are
also affected by oligomerization of ICP4 and extensive post-
translation modification, at least some of which are dependent on
additional HSV-1 proteins such as ICP27 [39]. As adenoviral
expression of ICP4 was sufficient to drive transcription at the
Abundance is expressed as fold induction relative to uninfected cells using the geometric mean of fold induction values from the housekeeping
genes b-actin, TBP and PPIA. Statistical significance determination is also relative to uninfected cells. (** p,.01, * p,.05). Figures are representative of
2 experiments with an n=4/group. Bars denote 6 SEM.
doi:10.1371/journal.ppat.1002278.g008
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that post-translational modifications of ICP4 mediated by other
HSV-1 proteins are not required for transcription initiation of
VEGF-A. Instead, native ICP4 interaction with non-consensus
elements or additional, possibly constitutively expressed DNA
binding factors are sufficient to allow ICP4-dependent transcrip-
tion of VEGF-A.
The effects of VEGF-A differ appreciably depending on isoform
[7,13,59]. VEGF-A isoforms are generated by alternative splicing
and vary in both extracellular matrix affinity and receptor
signaling cascades elicited [7,13]. HSV-1 ICP27 inhibits splicing
[60] and may alter VEGF-A isoform expression from infected
cells. VEGF-A expression during HSV-1 infection has been shown
to drive both hem- and lymph-angiogenesis. The hemangiogenic
consequences of VEGF-A expression are to be expected but the
strongly pro-lymphangiogenic impact of HSV-1 elicited VEGF-A
is at odds with studies showing only mild lymphodilation following
expression of the most common VEGF-A isoforms [14]. VEGF-A
expressed by HSV-1 infected cells may differ in either isoform or
post-translation modifications and these differences may be
responsible for disparate lymphangiogenic effects. Alternatively,
expression of additional cytokines may alter the effects of VEGF-
A. IL-1 and IL-6 promote angiogenesis during HSV-1 keratitis
[42]. Moreover, we have identified another cytokine required
along with VEGF-A for lymphangiogenesis during infection.
VEGF-A affects several systems that are not directly related to
(lymph)angiogenesis. VEGF-A modifies dendritic cell function
through ligation of DC expressed VEGFR-2, which inhibits
maturation [53]. VEGF-A suppresses CCL21 expression by
lymphatic endothelial cells, reducing DC migration to lymphatics
[61], and ligation of neuronal- expressed VEGF receptors induces
the growth of neuronal axons [54]. It remains to be seen whether
HSV-1 elicited VEGF-A differs from naturally expressed forms
with regards to suppression of DC maturation or neuronal axon
growth.
In summary, our data provide conclusive evidence that HSV-1
drives expression of VEGF-A promoting angiogenic sequelae
characteristic of ocular HSV-1 infection [8,12,41]. Not only was
VEGF-A transcription dependent on the HSV-1 transactivator
ICP4, the VEGFR-1 ligand PGF was also transcriptionally up-
regulated in an ICP4- dependent fashion. The promoters between
VEGF-A and PGF are highly homologous [62]. Future studies will
examine the role of ICP4 in the expression of other PGF and the
impact of ICP4 dependent expression of VEGFs on the host
immune response, viral replication, and angiogenesis.
Materials and Methods
Ethics Statement
Animal treatment was consistent with the National Institutes of
Health Guidelines n the Care and Use of Laboratory Animals. All
experimental procedures were approved by the University of
Oklahoma Health Sciences Center and Dean A. McGee Eye
Institutes’ Institutional Animal and Care Use Committee under
the approved IACUC protocol number 10-024.
Immunofluorescence Microscopy
Corneas were prepared and stained for specific antigens as
previously described [63]. The sources of antibodies used are as
follows; rabbit anti-HSV-1 and mouse anti-HSV-1 ICP4 (Abcam),
goat anti-GFP (Serotec), Dylight 549 donkey anti-rabbit and FITC
bovine anti-goat (Jackson ImmunoResearch). Images were taken
using an Olympus IX81-FV500 epifluorescence/confocal laser-
scanning microscope.
Cytokine Measurement
Human and mouse VEGF-A levels were measured by cytokine
bead array using a Bio-plex suspension array system (Bio-Rad) as
previously described [64], with multiplex kits provided by
Millipore.
HSV-1 Infection and Mice
Male C57BL/6, B6129, MyD882/2 and TRIF2/2 mice
were purchased from Jackson Laboratories. Transgenic reporter
mice expressing GFP under the proximal VEGF-A promoter were
the generous gift of Dr. Brian Seed (Harvard University) and were
constructed on an FVB background as previously described [65].
Mice with a floxed VEGF-A allele were generated as previously
described [66]. A breeder pair was provided by Genentech.
CD1182/2 mice were maintained in the OUHSC barrier.
Anesthetized mice were infected with HSV-1 by scarifying the
cornea with a 25 gauge needle and applying 10
5 pfu of HSV-1 per
cornea. GFP reporter expression was visualized by secondary
detection of GFP. Mice used were between 6 weeks and 6 months
old and age matched controls were employed in each experiment.
Cells and Virus
THCE cells were the generous gift of Dr. Jerry Shay (UT
Southwestern) and were maintained in keratinocyte serum free
media (Invitrogen) supplemented with 0.15 ng/ml EGF and
0.25 mg/ml bovine pituitary extract. Human 293 cells were
maintained in DMEM (Gibco) supplemented with 10% FBS
(Gibco). Primary human dermal keratinocytes (Lifeline Cell
Technology) were maintained in complete Dermalife medium
(Lifeline Cell Technology). HSV-1 virus stocks were propagated
using Vero cells. The HSV-1 ICP4
2 null virus, n12, is a nonsense
mutant with a premature stop codon that only encodes the N-
terminal 25% of the ICP4 protein [67] (generously provided by
Dr. Neal Deluc, University of Pittsburgh). The HSV-1 OBP
2 null
virus, hr94, contains a lacZ reporter gene insertion that disrupts
the origin binding protein (UL9) open-reading frame [59]
(generously provided by Dr. Sandra Weller, University of
Connecticut Health Sciences Center). The HSV-1 ICP0
2 null
virus, 7134, contains a lacZ open-reading grame exchanged in
place of the ICP0 open-reading frame (generously provided by the
late Dr. Priscilla Schaffer) [68]. HSV-1 d27-1 (ICP27
2) null virus
was a kind gift of Steve Rice (University of Minnesota Medical
School, Minneapolis) [35]. HSV-1 expressing Cre recombinase
under the ICP0 promoter was generated as described [69]. The
parental strain HSV-1 SC16 was a gift from Dr. Weiming Yuan
(University of Southern California, Los Angeles, CA). AdrtTA as
well as AdNull and the TRE-regulated ICP4-expressing vector
AdICP4 were constructed as previously described [68].
Reporter Plasmids and Luciferase Assays
LuciferasereporterplasmidsbasedonPromega’spGL3luciferase
reporter vector with luciferase driven by the sequences 22048/+50,
21290/+50, 2790/+50, 2415/+50, 2268/+50, 285/+50, 252/
+50 relative to the transcription start site of the human VEGF-A
gene were constructed as previously described [70] and generously
provided by Dr. Paul Fox (The Cleveland Clinic). For assays testing
the importance of specific promoter elements within luciferase
reporter plasmid 285/+50, a new vector driven by bp 288 to +55
ofthehumanVEGF-Atranscriptionstart sitewasconstructedasthe
original construction of 288/+50 removed the MCS site of pGL3,
complicating further manipulations. The new vector, pVA8855,
was created by amplifying the 288 to +55 base pair region of
pLuc2098 using the primers.
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GCCGGG-39.
VAProx8855-HindIII-Rev-59-TTCAGT AAGCTT CCCCC-
AGCGCCACGACCTCC-39 and digesting the resulting PCR
fragment and vector pGL3 in XhoI and HindIII (Promega) and
ligated with T4 DNA ligase (Promega). The sequence integrity of
the resulting plasmid was verified and luciferase expression
following HSV-1 infection between pLuc135 and pVA8855 did
not significantly differ. Site specific mutations of either EGR-1
consensus sequences or of the three GC boxes within pVA8855
were generated by PCR directed mutagenesis using Hotstart
Turbo PFU DNA polymerase (Stratagene) and degradation of the
original plasmid using Dpn I (Promega). The base sequence within
pVA8855 corresponding to the region between 288 to 250 bp of
the human VEGF-A promoter and sequences following mutation
are listed below, all of which were verified by DNA sequencing.
pVA8855 (288/250) CCCGGGGCGGGCCGGGGGC-
GGGGTCCCGGCGGGGCGGAG
DEGR-1 CCCGGGGCGGGCTAGGGGCGGGGTCCC-
TAAGGGGCGGAG
DGC Box1 CCCAACACAGGCCGGGGGCGGGGTCCC-
GGCGGGGCGGAG
DGC Box2 CCCGGGGCGGGCCGGAACACAGGTCC-
CGGCGGGGCGGAG
DGC Box3 CCCGGGGCGGGCCGGGGGCGGGGTCC-
CGGCAACACAGAG
DGC Box1+2 CCCAACACAGGCCGGAACACAGGTCC-
CGGCGGGGCGGAG
DGC Box1+3 CCCAACACAGGCCGGGGGCGGGGTC-
CCGGCAACACAGAG
DGC Box2+3 CCCGGGGCGGGCCGGAACACAGGT-
CCCGGCAACACAGAG
DGC Box1+2+3 CCCAACACAGGCCGGAACACAGGT-
CCCGGCAACACAGAG
The primers used to generate above mutants are as follows;
DEGR-1 For 59-GCGGGCTAGGGGCGGGGTCCCTAAG-
GGGCGGAG-39 Rev 59-CTCCGCCCCTTAGGGACCCCGC-
CCCTAGCCCGC-39
DGC Box1 For 59-GGGCTCGAGCCCAACACAGGCC-
GGGGGCG-39 Rev 59-GCC CCCGGCCTGTGTTGGGCT-
CGAGCCCG-39
DGC Box2 For 59- GGGCGGGCGGAACACAGGTCC-
CGGCG-39 Rev 59-GCCGGGACCTGTGTTCCGGCCCG-
CCCCG-39
DGC Box3 For 59-GGTCCCGGC AACACAGAGCCAT-
GCGCC-39 Rev 59-GGCGCA TGGCTCTGTGTTGCCGGG-
ACC-39
DGC Box1+2 For 59-GGGCTCGAGCCCAACACAGGCCG-
GAACACAG-39 Rev 59-CTGTGTTCC GGCCTGTGTTG-
GGCTCGAGCCC-39
Luciferase assays were performed by plating 25,000 293 cells or
primary human dermal keratinocytes per well of a 96 well plate
and transfecting cells the following day with 250 ng of plasmid per
well and Lipofectamine 2000 (Invitrogen) per to the manufactur-
er’s instruction. At 48 hours after transfection, transfected cells
were infected with 3 pfu per cell of HSV-1 and luciferase activity
was determined at the indicated times post infection relative to
HSV-1 infection using Promega’s firefly Luciferase Assay System
per the manufacturer’s instructions.
Nuclear and Cytoplasmic Protein Extraction and EMSA
Nuclear and cytoplasmic extracts of 293 cells were harvested
using NE-PER nuclear and cytplasmic protein extraction kit
(Thermo Scientific). Protease activity was inhibited by addition of
16Calbiochem Protease Inhibitor Cocktail. Protein concentration
of the extracts was measured using BioRad BCA protein assay.
The protein concentrations of nuclear and cytoplasmic extracts
were normalized to 1000 mg/mL using NE-PER nuclear and
cytoplasmic extraction buffers, respectively.
Oligonucleotides for EMSA were either chemically synthesized
or generated by PCR amplification using Hotstart Turbo PFU
DNA polymerase. Oligonucleotides of pVA8855, pVA8855
DEGR-1, pVA8855 DGC Box 1, pVA8855 DGC Box 2,
pVA8855 DGC Box 3, pVA8855 DGC Boxes 1 and 2, pVA8855
DGC Boxes 1 and 3, pVA8855 DGC Boxes 2 and 3, pVA8855
DGC Boxes 1 and 2 and 3, were generated using primers
biotinylated primers; biotin-59-TAGCCCGGGCTCGAGCC-39
and biotin-59-GAATGCCAAGCTTCCCCCAG-39 which ampli-
fies a fragment corresponding to bp 288 to +55 relative to the
transcription start site and biotin-59-GCGGAGCCATGCGCCC-
39 and biotin-59-GAATGCCAAGCTTCCCCCAG-39 which am-
plifies a fragment corresponding to bp 250 to +55 relative to the
transcription start site. Specific binding was verified by analyzing
nuclear protein binding to biotinylated oligonucleotides spanning a
sequence of the human VEGF-A promoter that was irrelevant to
HSV-1 induced transcription of VEGF-A (21513 to 21338 bp
relative to the transcription start site), generated using the primers
Biotin-59-AGGCCTCAGAGCCCCAACTTTG-39 and biotin-59-
CCTTACCTCCAAGCCCCCTTTTCC-39. To analyze EMSA
shifts corresponding to base pairs 288 to 250 bp of the human
VEGF-A promoter, the wild-type oligonucleotide 288-50WT 59-
AGCCCGGGGCGGGCCGGGGGCGGGGTCCCGGCGGGG
CGGAGCCAT-39, or the GC box mutated corresponding
oligonucleotide 288-50DGC 59- AGCCCAACACAGGCCG-
GAACACAGGTCCCGGCAACACAGAGCCAT-39. Binding of
HSV-1 infected cell nuclear protein extracts was competitively
inhibited using the ICP4 consensus containing oligonucleotide 59-
CAC TAT CGT CCA TAC CGA CCA CAC CGA CGA A-39.
EMSAs were performed using Thermo Scientific’s LightShift
Chemiluminescent EMSA Kit according to the manufacturer’s
protocol with the exception that instead of the included EMSA
binding buffer, the binding buffer used was composed as follows;
10 mM Tris-HCl, 5 mM MgCl2, 0.035% b-mercaptoethanol,
0.1% Triton X-100, and 2.5% glycerol (Sigma) at pH 7.5. Briefly,
the procedure was as follows. Probe (20 femtomoles per 20 mL
reaction volume) was incubated for 20 minutes in binding buffer
with 2 mg of nuclear protein extract with or without 1.5 mL of anti-
ICP4 antibody or isotypic control. Following binding, the reaction
was electrophoresed in 0.56TBE buffer in a 5% polyacrylamide
gel (BioRad) using the BioRad Criterion cell system. Electropho-
resed probe was transferred to a BioRad Zeta-probe nylon
membrane and biotinylated oligonucleotide was detected via
Streptavidin-horseradish peroxidase-mediated luminescence. Lu-
minescence was detected with a FLUOstar Omega plate reader
(BMG Labtech). Luminescence was normalized as luciferase units
relative to the intensity of luminescence detected in non HSV-1
infected 293 cells transfected with the promoterless luciferase
control vector pGL3.
Real-time PCR
Corneas were harvested, and RNA was isolated at indicated
time points PI using Trizol as per the manufacturer’s instructions
(Invitrogen). After RNA isolation, 2 mg RNA per sample was
converted to cDNA using an RT system (Promega) using random
primers according to the manufacturer’s instruction. Samples were
then analyzed via real-time PCR using Sybr Green supermix (Bio-
Rad Laboratories) via an iCycler (Bio-Rad Laboratories) as
previously described [71]. The abundance of VEGF-A/C/D
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2DDCt. For analysis of VEGF-A up-regulation in THCE cells,
VEGF-A fold induction was determined using a panel of three
housekeeping genes to control for effects of HSV-1 on house-
keeping gene expression. VEGF-A, B, C, D, or PGF cDNA
relative to b-actin, TBP, or PPIA was calculated as described for b-
actin, and the geometric mean of the threefold induction values
was taken as being the individual fold induction for the respective
sample. VEGF-C and VEGF-D were not detected in human 293
cells or HPKs in our hands. The validity of these primers has
already been verified previously by other groups [72,73]. THCE
cells were plated at densities of 3610
5 cells per well in 12-well
plates and then infected with 3 pfu per cell HSV-1 the next day
before harvesting RNA at the indicated time point using Trizol.
Primers were purchased from Sigma-Aldrich and sequences used
were as follows: Mu VEGF-A forward, 59-CTGCTGTACCTC-
CACCATGC-39; Mu VEGF-A reverse, 59-TCACTTCATGG-
GACTTCTGCTCT-39; Mu VEGF-C forward, 59-CTG-
fGGAAATGTGCCTGTGAATG-39; Mu VEGF-C reverse, 59-
ATTCGCACACGGTCTTCTGTAAC-39; Mu VEGF-D for-
ward, 59-CAAGACGAGACTCCACTGCC-39; Mu VEGF-D
reverse, 59-GCACTCACAGCGATCTTCATC-39;M ub-actin
forward, 59-CTTCTACAATGAGCTGCGTGTG-39;M ub-ac-
tin reverse, 59-TTGAAGGTCTCAAACATGATCTGG-39;H u
VEGF-A forward, 59-AGGAGGAGGGCAGAATCATCA-39;
Hu VEGF-A reverse, 59-CTCATTGGATGGCAGTAGCT-39;
Hu VEGF-B forward, 59-TCGCCGCACTCCTGCAGCTG-39;
Hu VEGF-B reverse 59-CGAGTATACACATCTATCCATGA-
CAC-39; Hu VEGF-C forward 59-TCAAGGACAGAAGAGAC-
TATAAAATTTGC-39 validated in reference 72; Hu VEGF-C
reverse 59-ACTCCAAACTCCTTCCCCACAT-39; Hu VEGF-D
forward 59-ATGGACCAGTGAAGCGATCAT-39, validated in
reference 78; Hu VEGF-D reverse 59-CAGCTTCCAGTCCTC-
CAGAGTGA-39; Hu PGF forward 59-GGAACGGCTCGTCA-
GAGGTG-39; Hu PGF reverse 59-CGACGTCCACCAGCC-
TCTC-39;H ub-actin forward, 59-AGCCTCGCCTTTGCCGA-
39;H ub-actin reverse, 59-CATGTCGTCCCAGTTGGTGAC-
39; Hu TBP forward, 59-TGCACAGGAGCCAAGAGTGAA-39;
Hu TBP reverse, 59-CACATCACAGCTCCCCACCA-39;H u
PPIA forward, 59-GTCAACCCCACCGTGTTCTT-39, PPIA
reverse, 59-CTGCTGTCTTTGGGACCTTGT-39, Hu EGR-1
For 59-CAGCCCTACGAGCACCTGACC-39, Hu EGR-1 Rev
59-GAGTGGTTTGGCTGGGGTAAC-39.
For assays of VEGF-A transcript following infection with HSV-
1 and treatment with specific inhibitors, the following concentra-
tions were used throughout the 12 hour course of the assay;
cycloheximide (Sigma) 100 mg/mL, acyclovir (Sigma) 200 mM,
and U0126, SB206580, and SP600125 (all purchased from Sigma)
were used at concentrations of 10 mM.
Reduction of EGR-1 via siRNA
To reduce EGR-1, 293 cells were plated in 24 plates at a density
of 10
5 cells per well in DMEM without antibiotics. Cells were
treated with either siPort Amine transfection reagent, or with
transfection reagent and either negative control siRNA (4390843
Ambion), or siRNAs against EGR-1 (4538 and 4539 Ambion) with
siRNAs applied at a final concentration of 20 nM in serum free
Optimem (Invitrogen). After a 24 hour incubation, medium was
removed and replaced with DMEM without antibiotics, and the
plate was used after an additional 24 hour incubation. Reduction
of EGR-1 was verified by real time RT-PCR to be greater that
60% in both 4538 and 4539 uninfected groups relative to negative
siRNA controls and EGR-1 transcript remainded below levels in
negative control-treated uninfected cells even 12 post HSV-1
infection.
Statistics
Comparisons between multiple treatment groups were per-
formed using one-way analysis of variance and Tukey’s multiple
comparison tests. All statistical analysis was performed with
GBSTAT (Dynamic Micro Systems).
Supporting Information
Figure S1 GC boxes and nuclear protein binding. (A)
Diagram of EMSA probe containing base pairs 288 to 250 of the
human VEGF-A promoter (288-50WT) or a GC box mutated
derivative (288-50DGC) used to detect GC box dependent
nuclear protein binding. (B) EMSA image of either wild-type or
GC box mutated probe incubated with 0, 6, or 12 hour PI nuclear
protein extracts harvested from 293 cells infected with 3 pfu per
cell of HSV-1 McKrae. (C) Despite not observing GC box
dependent binding to 288-50 wild type probe, a probe containing
a single, isolated GC box bound nuclear proteins in extracts
harvested from 293 cells at 0, 6, and 12 hours PI with 3 pfu per
cell HSV-1 McKrae. Figures B and C are representative of 3
experiments.
(TIF)
Figure S2 GC boxes are not required for ICP4 binding.
(A) EMSA using nuclear proteins extracts harvested from 293 cells
at 6 hours PI with 3 pfu per cell HSV-1 McKrae incubated with
either wild type 288 to +55 bp probe (pVA8855) or GC box
mutated probe (DGC123) and either isotypic control or antibody
against ICP4. (B) Diagram of probes spanning the proximal
human VEGF-A promoter used determine the ICP4 binding
region. (C) EMSA images using 293 nuclear protein extracts at
6 hours PI with either 288 to 250 base pair probe or 250 to +55
base pair probe with either isotypic control or antibody against
ICP4. Free probe (P) indicated by a solid arrow denotes native
probe/nuclear protein complex whereas the hollow arrow denotes
antibody supershifted complex. EMSA images are representative
of 3 experiments.
(TIF)
Figure S3 ICP27 is not required for activation of
transcription at the VEGF-A promoter. (A) Immunofluo-
rescence images of 293 cells stained with anti ICP4 monoclonal
antibody or control IgG (red) at the indicated time PI with HSV-1
KOS or ICP27 deleted virus (nuclei stained with DAPI shown in
blue). (B) ICP4 staining (red) of human 293 cells at 12 hours PI
with either HSV-1 KOS or ICP27- virus. Nuclei are denoted by
dashed white lines. (C) Human 293 cells were transfected with
pVA8855 luciferase reporter plasmid for 48 hours, and were
assayed for luciferase activity at the indicated times PI with 3 pfu
per cell of HSV-1 KOS, ICP4
2 null, or ICP27
2 null virus.
Luciferase activity was normalized to luminescence values of
uninfected human 293 cells transfected with pGL3. Representative
of two experiments (**, p,0.01). Bars denote 6 SEM.
(TIF)
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